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ABSTRACT
Objective: Acute postoperative pain is experienced by the majority of hospitalized patients under-
going surgical procedures, with many reporting inadequate pain relief and/or high levels of dissatisfac-
tion with their pain management. Patient-controlled analgesia (PCA) ensures patient involvement in
acute pain control, a key component for implementing a quality management system. This narrative
article overviews the clinical evidence for conventional PCA and briefly discusses new, non-invasive
PCA systems, namely the sufentanil sublingual tablet system (SSTS) and the fentanyl iontophoretic
transdermal system (FITS).
Methods: A Medline literature search (“patient-controlled analgesia” and “acute postoperative pain”)
was conducted to 1 April 2017; results from the main clinical trials are discussed. Additional literature
was identified from the reference lists of cited publications.
Results: Moderate to low quality evidence supports opioid-based intravenous PCA as an efficacious
alternative to non-patient-controlled systemic analgesia for postoperative pain. However, despite the
benefits of PCA, conventional intravenous PCA is limited by system-, drug- and human-related issues.
The non-invasive SSTS and FITS have demonstrated good efficacy and safety in placebo- and intraven-
ous morphine PCA-controlled trials, and are associated with high patient/healthcare practitioner satis-
faction/ease of care ratings and offer early patient mobilization.
Conclusions: Evidence-based guidelines for acute postoperative pain management support the use of
multimodal regimens in many situations. As effective and safe alternatives to conventional PCA, and
with the added benefits of being non-invasive, easy to use and allowing early patient mobilization, the
newer PCA systems may complement multimodal approaches, or potentially replace certain regimens,
in hospitalized patients with acute postoperative pain.
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The majority of patients who undergo surgical procedures
experience acute postoperative pain, but evidence suggests
that less than half report adequate postoperative pain
relief1,2. Moreover, many patients report a high level of dis-
satisfaction with their pain management3–5. Numerous recent
and ongoing initiatives at the national and international
level, including the 2001–2011US congress-initiated “Decade
of Pain Control and Research”6, and the joint 2017
International Association for the Study of Pain (IASP)/
European Pain Federation (EFIC) “Global/European Year
Against Pain After Surgery”7, have increased awareness
among key stakeholders. In addition, studies have shown
that the introduction of acute pain services and/or acute
pain management programs can be associated with
improved acute postoperative pain management, and good
pain control has become an indicator of quality of care and
good clinical practice8–12. Nevertheless, although adequate
treatment of acute postoperative pain can improve patient
quality of life and satisfaction with care, as well as enhance
clinical resource management and reduce long-term costs of
care, acute pain remains undertreated and its management is
suboptimal13.
There are numerous short- and long-term consequences
of inadequately treated acute pain, including hyperglycemia,
insulin resistance, an increased risk of infection, decreased
patient comfort and satisfaction and the chronification of
pain13–16. The processes responsible for the transition from
acute postoperative or post-traumatic pain to pathological
chronic pain are complex and poorly understood15,17,18.
Biological, psychological and social/environmental factors,
and known polymorphisms in human genes, are all involved
in perpetuating the pain18.
Valid, reliable and active assessment of pain in the post-
operative phase is an important factor in achieving improved
postoperative pain organization and management in hospi-
tals19,20. A study using repeated annual audits over a 3 year
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period in the general surgery and orthopedic departments of
a large university hospital setting led to the introduction of
mandatory training in postoperative pain management for all
key stakeholders, upgraded care guidelines/protocols and
regular staff meetings20. During the 3 year period, the assess-
ment of pain according to protocols increased from 71% to
91% in the surgical wards and from 60% to 88% in the
orthopedic wards20.
Persistent acute postoperative pain can be prevented
using a variety of multidisciplinary team approaches (e.g.
physician-led, nurse-led, pharmacist-led and/or patient-con-
trolled), including multimodal pharmacological strategies,
psychological strategies, modified surgical techniques, pro-
cedure-specific postoperative pain management and
enhanced postoperative recovery programs21–25.
Indeed, many preoperative, intraoperative and postopera-
tive interventions and management strategies are available
for reducing and managing postoperative pain. Interestingly,
in a large survey involving >16,000 surgical patients from 17
countries “correlates of satisfaction” with pain treatment
were evaluated26. Three items showed strong association
with overall satisfaction: (1) more pain relief; (2) greater par-
ticipation in decisions regarding treatment; (3) no desire to
have received more treatment. The authors concluded that
while the patients’ satisfaction with postoperative pain treat-
ment was associated with their actual pain experience, it was
more strongly influenced by their impressions of improve-
ment and appropriateness of care26.
Patient involvement in pain control is a key component
for the implementation of a quality management system in
the surgical setting25,27,28. A rational extension of this goal is
allowing patients to control an on-demand system which
permits them to manage their own pain relief29.
Patient-controlled analgesia: background
One of the founding pioneers of patient-controlled analgesia
(PCA), Dr. Philip H. Sechzer, maintained that “if patients had
more control of their medication, their anxiety and pain
would be less severe, and they would dose themselves with
less medication”30. Dr. Sechzer originally introduced “patient-
controlled analgesic demand systems” into medical practice
in the 1960s31,32.
PCA enables the patient to self-administer predetermined
doses of an analgesic when they deem it necessary. The spe-
cific doses are programmed by a trained healthcare profes-
sional, and the device is also programmed to limit the
administration of each dose or a cumulative amount of drug
over a specific time interval. The technique has progressed
over recent decades and sophisticated microprocessor-con-
trolled infusion pumps are currently used to deliver the
required doses of analgesic33. PCA typically involves intraven-
ous (IV) opioid delivery, generally using morphine, but may
include other drugs (such as NSAIDs or local anesthetics) or
other routes of administration (for example, epidural, sub-
cutaneous, transdermal or nasal administration)33. Indeed,
PCA represents a conceptual framework for the administra-
tion of analgesics. PCA is commonly used for acute
postoperative pain, but it can also be used for the manage-
ment of other types of acute pain such as in the hospital
emergency department33. It has been documented that acute
pain is not controlled adequately in the emergency care set-
ting34,35. This observation of suboptimal pain management
may extend to situations in which the patient requires trans-
fer between hospitals (usually for a higher level of care) in
emergency vehicles36,37. In some jurisdictions, ambulances
are staffed by paramedics with basic life support training;
doctors and nurses are not available to administer analgesics.
Therefore, although there is currently insufficient clinical evi-
dence or guidelines regarding the use of PCA for patients
with acute injury during transfer to a higher level of care38,
there is a potential role for PCA to provide sufficient acute
pain management in this setting.
The aim of this commentary is to provide an overview of
the clinical effectiveness and safety of, and patient satisfac-
tion with, conventional PCA for acute postoperative pain in
the hospital setting, and briefly discuss new, non-invasive
PCA systems, namely the sufentanil sublingual tablet system
(SSTS; Zalviso1) and the fentanyl iontophoretic transdermal
system (FITS; Ionsys2), in this clinical setting.
Methods
This commentary is based largely on recently published best
clinical evidence27,39,40, supplemented with new literature
published since those publications (in 2015) and data from
current clinical practice guidelines for the management of
postoperative pain. Therefore, a literature search was con-
ducted in the Medline database using the terms “patient-
controlled analgesia” and “acute postoperative pain” from 1
January 2015 to 1 April 2017 (113 records) and results from
the main clinical trials, published in English, are discussed.
Additional literature was identified from the reference lists of
cited publications.
Overview of patient-controlled analgesia
This section provides an overview of the clinical evidence
regarding PCA, based largely on a recently published
Cochrane systematic review40 and clinical evidence evaluated
with scientific rigor by the Australia and New Zealand
College of Anaesthetists (ANZCA) and Faculty of Pain
Medicine (FPM)39.
The recent Cochrane review of 49 randomized, controlled
trials (n¼ 3412) showed that there is moderate to low quality
evidence that opioid-based IV PCA is an efficacious alterna-
tive to non-patient-controlled systemic analgesia for postop-
erative pain control40. For the primary outcome, participants
receiving IV PCA had lower visual analog scale (VAS) pain
intensity scores versus non-PCA over most time intervals. For
example, VAS scores over 0 to 24 hours were 9 points lower
(95% confidence interval [CI] 13 to 5; moderate quality
evidence) and over 0 to 48 hours were 10 points lower (95%
CI -12 to -7; low quality evidence). Among the evaluated sec-
ondary outcomes, participants were more satisfied with PCA
(81% versus 61%, p¼ .002) and consumed higher amounts of
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opioids than non-PCA recipients (0 to 24 hours, 7mg more of
intravenous morphine equivalents, 95% CI 1mg to 13mg)40.
With regard to safety, individuals receiving PCA had a higher
incidence of pruritus (15% versus 8%, p¼ .01) but had a simi-
lar incidence of other adverse events. In addition, there was
no overall between-group difference in the length of hos-
pital stay40.
A pooled analysis of data from 165 studies in approxi-
mately 20,000 patients showed that patients who received
intramuscular (IM) opioid analgesia were approximately two-
to three-fold more likely to experience moderate-to-severe
(67.2% vs. 35.8%) or severe (29.1% vs. 10.4%) acute postoper-
ative pain compared with individuals who received IV PCA41.
The largest randomized, controlled study compared the
efficacy and safety of IV PCA versus IM analgesia in 328
patients after major abdominal surgery (cholecystectomy: 105
patients; hysterectomy: 223 patients)42. Patients receiving
PCA required less total analgesia (cholecystectomy: 663mg
vs. 809mg; hysterectomy: 696mg vs. 1027mg), had a shorter
length of hospital stay (cholecystectomy: 4.5 days vs. 6.3
days; hysterectomy: 4.5 days vs. 4.8 days) and lower average
total costs (drugs, nursing and pharmacy time: US$13.43 vs.
US$41.33) than patients receiving IM analgesia. No complica-
tions attributable to the route of administration
were reported42.
Taken together, these findings highlight the overall
importance and benefits of PCA versus conventional non-
PCA approaches. Indeed, based on the clinical evidence dis-
cussed above, current pain management guidelines support
the use of PCA for postoperative pain management. For
example, recently published clinical practice guidelines from
the American Pain Society, with input from the American
Society of Anesthesiologists, recommend that IV PCA be used
for postoperative systemic analgesia when the parenteral
route is needed (strong recommendation, moderate-quality
evidence)25. These recommendations for the use of PCA are
also supported in other management and clinical practice
guidelines43. German guidelines44,45 note that meta-analyses
show that IV PCA systems achieve better analgesia compared
with conventional IM, subcutaneous (SC) and IV regi-
mens46,47, and are preferred by patients48. Furthermore, the
German guidelines note that controlled IV analgesia applied
by nurses can be comparable to that achieved with IV PCA,
but only if it is carried out systematically and continuously49.
Given that the fundamental difference between the two
treatment groups in the latter study is the avoidance of
nurses having to repeatedly attend to and supervise the
patient to assess pain relief and administer analgesia, the
findings imply that a more resource-intensive approach may
be required with controlled IV analgesia than with IV PCA to
achieve similar levels of analgesia49.
Despite the benefits of PCA, conventional approaches are
associated with some drawbacks. One of the limitations of IV
PCA is the large degree of variability in the parameters used
in clinical studies (e.g. bolus doses, lockout intervals and
maximum permitted cumulative doses), leading to uncer-
tainty about the optimal PCA program and possibly restrict-
ing the flexibility, and efficacy, of the technique. Moreover, in
order for patients to receive maximum benefit from IV PCA,
individual prescriptions may need to be adjusted50.
Data from a prospective, multicenter, observational study
showed that IV PCA in acute postoperative pain management
is labor intensive and involves numerous time-consuming
tasks, oversight of IV PCA and ongoing staff training51.
Other potential drawbacks to conventional IV PCA result
from the complex technology required, including the need
for a patent IV line and tethering of the patient to an IV PCA
pump mounted on an IV pole which can result in infection,
reduced mobility and analgesic gaps as a consequence of IV
catheter infiltration or IV tubing obstruction52,53. In addition,
IV PCA is prone to human dosing errors due to the use of a
programmable pump, many of which cause harm to patients
and add a significant cost burden to healthcare systems54,55.
A 5 year retrospective analysis (2000–2004) of a US voluntary
medication error-reporting database showed that 1% (9571/
919,241) of all reported errors were PCA-related and, of
these, 38% involved an improper dosage or quantity, while
17.4% involved an omission and 17.3% an unauthorized or
wrong drug (Figure 1). Human factors were identified as the
main cause of PCA errors, with equipment issues (19.5%) and
similar drug names and product packaging (11.6%) also
implicated. The most common factors which contributed to
PCA-associated errors were distractions (37.8%) and inexperi-
enced staff (26.3%)54. Drugs most frequently associated with
PCA errors were morphine (49.2%), hydromorphone (21.6%),
meperidine (11.8%), fentanyl (4.6%) and naloxone (0.9%)54.
Programming errors were also identified as the largest con-
tributory factor to critical incidents with conventional PCA
systems in a 5 year analysis (2002–2006) of data from an Irish
university hospital setting56.
Factors associated with IV PCA have resulted in relatively
low uptake of this treatment modality, despite it being
included in many guidelines52,53,55,57,58. Indeed, the propor-
tion of postoperative patients receiving IV PCA remains rela-
tively small despite the fact that, as discussed earlier, clinical
practice guidelines recommend PCA in preference to conven-
tional routes of administration; national surveys recorded
21.4% use of IV PCA in France59 and only 5% in Italy60.
Patient characteristics can also influence the use of con-
ventional PCA. A study in 100 patients who used only mor-
phine PCA for the first 24 hours after upper abdominal
surgery showed that male patients (n¼ 46) required signifi-
cantly more morphine than female patients (n¼ 54) to
achieve similar levels of pain relief (p< .05)61. There was an
inverse correlation between age and morphine consumption
in both males (r¼0.684, p< .00005) and females
(r¼0.502, p< .00005). No correlation was found between
morphine consumption and patient weight. The pattern of
hourly morphine consumption appeared to follow a diurnal
rhythm, with peak times of demand at 0900 and
2000 hours61. An inverse correlation between patient age and
morphine consumption was also observed in a large
(n¼ 1308) retrospective analysis of patients using postopera-
tive IV PCA over 3 days62. For all operations, weight, age,
procedures involving malignant disease and surgical sites
were significantly associated with total morphine consump-
tion62. Individual patient psychological factors can also play a
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role in the success or failure of using PCA; for example, an
individual’s decision to press the PCA button can be
impacted by confusion or fear, or behavioral beliefs about
their level of control33.
Whilst recognizing the underlying value and importance
of PCA and acknowledging the potential drawbacks of con-
ventional approaches to PCA, more recent clinical research
has focused on developing improved PCA systems.
Consequently, alternative noninvasive routes of administra-
tion have been evaluated, with the aim of simplifying the
process and avoiding errors; for example, noninvasive sublin-
gual and transdermal routes of PCA have been shown to be
both safe and effective compared with conventional intraven-
ous PCA. The following sections provide a brief overview of
recently introduced innovative needle-free PCA systems,
focusing specifically on the SSTS and the FITS.
Sufentanil sublingual tablet system
The sufentanil sublingual tablet system (SSTS) is a pre-pro-
grammed, non-invasive, handheld device which dispenses a
single sufentanil bioadhesive nanotablet (3mm in diameter,
0.75mm thickness; 15 lg), with a minimum 20minute inter-
dose lockout period63. The dispenser can be used by the
same patient over the course of 3 days of treatment; prefilled
cartridges contain 40 tablets (providing about a 2 day supply)
and cartridges are discarded after patient use. Sufentanil
nanotablets dissolve promptly when administered sublin-
gually64. The pre-programmed device uses a radiofrequency
identification thumb tag, which allows self-administration
only by the assigned patient (healthcare providers or patient
relatives cannot administer the drug); this aspect of the SSTS
decreases the most common issues associated with conven-
tional PCA systems. Moreover, the SSTS is able to display a
digital tablet count which allows the course of medication
demand to be assessed63.
The efficacy and safety of the SSTS have been demon-
strated in several phase II and phase III double-blind,
randomized, comparative clinical studies, conducted in
patients undergoing major open abdominal or orthopedic
surgery65–68.
In placebo-controlled studies, the SSTS was significantly
better than placebo with regard to the primary endpoint
(summed pain intensity difference [SPID] 48; p .001)65,67.
SPID and total pain relief (TOTPAR) scores were significantly
higher with the SSTS than with placebo from early time
points through to 72 hours65,67. In a phase III active-compara-
tor trial, the SSTS was associated with a more rapid onset of
analgesia (statistically significantly greater pain control at 1,
2, and 4 hours; all p< .01 compared with IV morphine PCA),
and higher success rates, based on patient global assessment
(PGA) and investigator global assessment (IGA) of the
method of pain control over 24, 48 and 72 hours66. Indeed,
78.5% and 65.6% of patients achieved success (“excellent” or
“good”) on the PGA over 48 hours (primary endpoint) in the
SSTS and IV morphine PCA groups, respectively, demonstrat-
ing non-inferiority as well as statistical superiority in favor of
the SSTS group (p¼ .007). Moreover, non-inferior pain relief
was sustained over a 48–72 hour period with the SSTS com-
pared with IV morphine PCA. Patient and nurse ease of care
(EOC) and satisfaction scores were significantly higher in
patients using the SSTS than in those using IV morphine
PCA; patients in the SSTS group reported significantly better




























Figure 1. Types of errors associated with conventional patient-controlled analgesia in a 5 year retrospective analysis of a US voluntary medication error-reporting
database. Data presented as totals (%) for the years 2000 to 2004, occurring in >1% of cases54.
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With regard to safety, the between-group incidences of
adverse events were similar in the phase III placebo-con-
trolled trial in patients undergoing open abdominal sur-
gery67, and in the IV morphine PCA trial66. However, in the
phase III placebo-controlled trial in patients undergoing
orthopedic surgery, there was a significantly higher incidence
of adverse events in the SSTS group compared with the pla-
cebo group (54% vs. 34%; p< .001). Across the three phase
III trials, discontinuation rates due to adverse events were
broadly similar (approximately 7% in both groups in the pla-
cebo-controlled trials; 7.3% [SSTS] vs. 10.0% [IV morphine
PCA])65–67. In the IV morphine PCA comparative study, signifi-
cantly fewer patients in the SSTS group than in the IV PCA
group experienced oxygen desaturation episodes <95%
(19.8% vs. 30.0%; p¼ .028)66.
Fentanyl iontophoretic transdermal system
The recently introduced, second-generation fentanyl ionto-
phoretic transdermal system (FITS) is a pre-programmed, nee-
dle-free, patient-activated drug delivery system which
comprises two components, a drug unit and a Separated
System with Enhanced Controller (SSEC), replacing a first-
generation integrated single-unit system which was with-
drawn from the market in 2008 due to the presence of corro-
sion in a small number of systems69.
Immediately prior to application of the FITS onto the
intact, non-irritated, non-irradiated skin of the patient, the
healthcare professional assembles the system by snapping
together the drug unit and SSEC. Each activation of the FITS
delivers a fixed 40 lg fentanyl dose at an electrical current of
170 lA, with a maximum of 80 doses every 24 hours (a max-
imum of 6 doses per hour, with a 10minute lockout after
each dose)69,70. The FITS must be removed and discarded
before bathing or if the patient requires defibrillation or
radiographic procedures; once it is removed, it is not possible
to reapply the system71.
The efficacy and safety of the FITS in postoperative pain
management have been demonstrated in several published
placebo- and IV morphine PCA-controlled phase III clinical tri-
als conducted with the original delivery system in patients
undergoing orthopedic, abdominal, thoracic or pelvic sur-
gery72–77. Meta-analyses have confirmed the efficacy of the
FITS, including its EOC profile, compared with conven-
tional PCA78–82.
The proportion of study withdrawals due to inadequate
analgesia (primary endpoint) was significantly lower in FITS
recipients compared with patients in the comparator group
in the placebo-controlled trials: 25.4% vs. 40.4% (p¼ .049)72
and 28.7% vs. 60.0% (p< .0001)73, regardless of the type of
surgery. The primary outcome measure in the four IV mor-
phine PCA-controlled trials was the success (“excellent” or
“good” ratings) for the PGA of the method of pain control
during the first 24 hours74–77. No statistically significant
between-group differences were reported for PGA in any of
the active comparator trials, indicating therapeutic equiva-
lence between the FITS and IV morphine PCA. Similar find-
ings were reported for IGA (secondary endpoint in all active
comparator trials).
A multicenter, randomized open-label, phase IV clinical
trial has also recently demonstrated that, at all time-points
following surgery out to 24 hours, patients treated with the
FITS were better able to mobilize than patients treated with
IV morphine PCA83. Although the study was stopped and
treatment terminated earlier than planned, patients in the
FITS group (n¼ 58) had a greater ability than those in the IV
morphine PCA group (n¼ 50) to mobilize at the time of stop-
ping the study drug, with an adjusted mean ability to mobil-
ize score (95% confidence intervals [CI] 0.14 (-0.19, 0.47) and
2.37 (1.98, 2.76) for the FITS and IV morphine PCA, respect-
ively; p< .001)83.
Two phase III studies identified a significantly higher early
discontinuation rate with the FITS compared with IV mor-
phine PCA75,76, and between-group differences in withdrawal
rates due to lack of efficacy/inadequate analgesia were sig-
nificantly higher in FITS recipients in the two studies (both
p< .05): 9.1% vs. 2.8%76 and 11.1% vs. 5.4%75. These findings
were supported in a subsequent meta-analysis, with the
authors speculating that discontinuations due to a lack of
efficacy, particularly in the early postoperative period, may
reflect the pharmacokinetic profile of fentanyl in the FITS84.
With regard to safety, treatment-emergent adverse events
(TEAEs) reported in the placebo- and IV morphine PCA-con-
trolled trials of the FITS were consistent with those expected
from opioid use, with the most frequent being nausea, fever,
vomiting and headache72–77. However, significantly more
opioid-related adverse events occurred in patients in the IV
morphine PCA group than in the FITS group (p¼ .03)70.
Discussion
Since its introduction about five decades ago, IV PCA has
been utilized widely for the successful management of acute
postoperative pain in the hospital setting, allowing patients
to self-titrate opioids, most often morphine.
Table 1. Key characteristics of an ideal patient-controlled analgesia (PCA) system for acute postoperative pain management.
Consistent and adequate pain relief across a range of surgical procedures
An acceptable safety and tolerability profile (applies to the PCA system and the drug(s) administered via PCA)
Ease of use (set-up, maintenance and administration) by the patient and healthcare providers
Minimal invasiveness
Improved quality of care
High levels of patient and nurse satisfaction
Allows patient mobility
Avoidance of analgesic gaps
Minimal technology-related complications
Compatible with current clinical care (e.g. physical therapy, activities of daily living, antithrombotic therapy)
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A recent evidence-based assessment from the ANZCA/FPM
noted that IV PCA provides better analgesia than conven-
tional parenteral opioid regimens, and is associated with
higher patient satisfaction than conventional non-patient-
controlled opioid analgesic regimens39. Overall, the assess-
ment also found that opioid administration by IV PCA
leads to higher opioid consumption and, despite a higher
incidence of pruritus, there was no difference in other opi-
oid-related adverse effects or hospital stay compared with
traditional methods of intermittent parenteral opioid admin-
istration39. Despite the clear benefits of conventional PCA
approaches, operator errors, particularly programming errors,
remain a common safety problem with IV PCA which often
leads to patient harm39. Also, although morphine is the most
commonly used opioid in IV PCA, evidence suggests that the
pharmacokinetic properties of morphine (long equilibration
half-time and active metabolites) may make it less suitable
for PCA use than other opioids39.
Consequently, a number of currently existing gaps in
patients’ postoperative analgesic treatment remain an issue
which could be improved. As noted previously, conventional
PCA has numerous limitations, related to both the adminis-
tered medication and the system used for administration.
Specific clinical disadvantages of IV PCA include the fact that
it is invasive, restricts patient mobility, requires external sup-
plies (e.g. power cables, tubing), and the necessity for pump
apparatus and programming, and extensive staff time and
resources. These limitations preclude conventional IV mor-
phine PCA from being considered an ideal PCA system. In
light of the key characteristics of an ideal PCA system (Table
1), two recently introduced innovative, non-invasive systems,
the SSTS and the FITS, have been designed to address the
shortcomings of IV PCA for the management of moderate to
severe acute postoperative pain in the hospital setting.
Both the pre-programmed SSTS and the FITS provide non-
invasive PCA and the efficacy and safety of these systems
have been demonstrated in randomized, controlled clinical
trials65–68,72–77. Compared with IV morphine PCA, both of the
new non-invasive systems have also been shown to improve
patient mobility and are associated with high patient and
healthcare practitioner ease of use/care ratings and high sat-
isfaction levels. Improved patient mobility may also aid
patient compliance with postsurgical physiotherapy goals
and shorten the length of hospital stay85–88. In overcoming
the existing shortcomings with IV PCA, the newer systems
may also help to reduce hospital costs associated with IV
PCA issues and errors55,81,89.
The availability of non-invasive PCA systems for the man-
agement of acute postoperative pain represents significant
progress in the field of PCA which has otherwise witnessed
only limited advances in the decades since its initial introduc-
tion. In light of the current emphasis which is being placed
on the importance of managing acute postoperative pain,
through awareness campaigns such as the joint 2017 IASP/
EFIC “Global/European Year Against Pain After Surgery”7, the
potential impact of newer PCA systems should not be
underestimated.
In summary, PCA represents a well established approach
to the management of acute postoperative pain. Current
evidence-based guidelines for the management of acute
postoperative pain support the use of multimodal regimens
and patient involvement (via the use of PCA) in many situa-
tions, although the exact components of effective multi-
modal care will vary depending on the patient, setting and
surgical procedure25. As effective and safe alternatives to
conventional IV PCA, and with the added benefits of being
non-invasive, easy to use and allowing early patient mobiliza-
tion, the newer innovative PCA systems may be suitable
complements for multimodal therapeutic approaches, or
potential replacements for certain regimens, in patients with
moderate to severe acute postoperative pain.
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